A real-world study showed that NSCLC patients with EGFR ex20ins mutations had lower overall survival (OS) and progression-free survival (PFS) than those with common EGFR mutations (EGFR ex19del and EGFR L858R). Here, EGFR is linked to non-small cell lung carcinoma.